Shandong Xinhua Pharmaceutical Company Limited의 최근 주당순이익은 $로, $0.11의 예상을 .
Shandong Xinhua Pharmaceutical Company Limited SHNXY의 지난 분기 매출 실적은 어땠나요?
Shandong Xinhua Pharmaceutical Company Limited의 지난 분기 매출은 $입니다.
Shandong Xinhua Pharmaceutical Company Limited의 매출 추정치는 얼마인가요?
명의 월스트리트 애널리스트에 따르면, Shandong Xinhua Pharmaceutical Company Limited의 매출 추정치는 $에서 $까지입니다.
Shandong Xinhua Pharmaceutical Company Limited의 수익 품질 점수는 얼마인가요?
Shandong Xinhua Pharmaceutical Company Limited의 수익 품질 점수는 /입니다. 이 점수는 수익성, 성장, 현금 창출 및 자본 배분, 레버리지의 네 가지 차원을 기반으로 합니다.
Shandong Xinhua Pharmaceutical Company Limited는 언제 수익을 보고하나요?
Shandong Xinhua Pharmaceutical Company Limited의 다음 수익 보고서는 2026-01-23에 발표될 예정입니다.
Shandong Xinhua Pharmaceutical Company Limited의 예상 수익은 얼마인가요?
월스트리트 애널리스트에 따르면 Shandong Xinhua Pharmaceutical Company Limited의 예상 수익은 $입니다.
Shandong Xinhua Pharmaceutical Company Limited은 수익 기대치를 충족했나요?
Shandong Xinhua Pharmaceutical Company Limited의 최근 수익은 $로, 기대치를 .
주요 통계
이전 종가
$18.19
시가
$18.19
일일 범위
$18.19 - $18.19
52주 범위
$18.19 - $18.19
거래량
100
평균 거래량
0
배당수익률
--
EPS(TTM)
0.80
시가총액
$899.9M
SHANDONG XINHUA PHARMACEUTICAL 란 무엇인가요?
Shandong Xinhua Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Zibo, Shandong and currently employs 7,296 full-time employees. Shandong Xinhua Pharmaceutical Co Ltd is a China-based company mainly engaged in the development, manufacturing and sales of chemical raw materials, pharmaceutical preparations and chemical products. The firm operates three segments. The Chemical Raw Materials segment is mainly engaged in the development, manufacturing and sales of raw materials for antipyretics and analgesics such as caffeine series, ibuprofen series, aspirin series, dopamine series, barbiturates and pipemidic acid. The Pharmaceutical Preparations segment is mainly engaged in the development, manufacturing and sales of tablets, injections and capsules such as pipemidic acid tablets, aminopyrine and nimodipine tablets. The Pharmaceutical Intermediates and Other Products segment is mainly engaged in the development, manufacturing and sales of pharmaceutical intermediates and other products. The firm mainly operates its business in the domestic market and overseas markets such as the Americas and Europe.